Abbott Labs Advances Atrial Fibrillation Treatment, Wireless⁤ Pacemaker Technology

Abbott Laboratories is⁢ reporting positive study results for its atrial fibrillation treatment⁣ and wireless pacemaker technology, potentially⁤ strengthening its ⁣position in⁤ the medical‍ technology market.

Volt PFA System Shows Promise for Atrial Fibrillation

Data from the Volt CE Mark Study, spanning 12 months, indicates the Volt PFA system is both safe and effective in treating atrial fibrillation. The study, ⁤which tracked⁢ long-term outcomes, confirmed the pulsed field ablation therapy’s efficacy.

The results, presented at the Heart Rhythm Society’s annual conference in 2025, highlighted the system’s success in treating‍ both paroxysmal (seizure-like) ⁤and persistent atrial fibrillation. The company believes that the Volt PFA system’s⁢ ability to achieve‍ results ⁢with fewer therapy applications could give it an edge over competing systems in the catheter⁢ ablation market.

Aveir Wireless Pacemaker Reaches Milestones

Abbott also announced progress with its Aveir⁢ wireless pacemaker ⁤technology. A feasibility study demonstrated the ⁤safety and performance⁣ of conduction system pacing (CSP), a technique that mimics ⁣the heart’s natural electrical rhythm by stimulating the left⁣ leg block⁣ area.

Successful implantation and the ⁣achievement of left ventricular stimulation are considered significant milestones.⁤ The Food and Drug Administration (FDA) has granted “breakthrough device” status to both the Aveir CSP ⁤system and its‍ associated ICD electrode,‍ underscoring their potential impact.

A ⁤larger approval study, ⁢ASCEND CSP, is underway with plans to enroll up to 414 patients at 70 locations globally. This study aims to finalize the assessment of the‍ Aveir system’s ⁢safety and effectiveness.

Future market ⁣Position

These technological advancements in cardiology signal Abbott’s commitment to innovation. Continued development and successful market introduction ‍of these systems⁣ are expected to be crucial for the company’s future market position.

Abbott Labs Advances Atrial Fibrillation Treatment,Wireless Pacemaker Technology: Your Questions ⁤Answered

Are you interested in the latest advancements in cardiology from Abbott Laboratories? This article breaks down their recent breakthroughs in atrial fibrillation treatment and wireless pacemaker technology,answering your ⁤key questions in a clear and concise format.

What ‍are the main advancements Abbott is reporting?

Abbott‍ Laboratories is highlighting positive study results for two key areas:

Atrial Fibrillation Treatment: Specifically, they are seeing promising ⁣results with the Volt PFA system.

Wireless⁤ Pacemaker ⁢Technology: They’ve made significant ⁣progress with their ‍Aveir wireless pacemaker, focusing on conduction system⁣ pacing (CSP).

These advancements possibly strengthen Abbott’s position in the medical technology market.

what is the Volt PFA system, and how does it treat atrial ⁤fibrillation?

The Volt PFA (Pulsed Field Ablation) system is a new approach to treating⁤ atrial fibrillation. Data from the Volt CE Mark study,a 12-month study,indicates it’s both safe⁢ and effective in treating this condition.

What type of atrial fibrillation was the Volt PFA system prosperous in treating?

the Volt PFA system showed success ⁢in treating both:

Paroxysmal Atrial Fibrillation: This is characterized by “seizure-like” episodes of irregular heart rhythm.

Persistent Atrial Fibrillation: This⁣ type involves longer-lasting or constant irregular heart rhythms.

What’s the advantage of the volt PFA system?

Abbott believes that ⁣the Volt PFA system’s ability to ‍achieve results with fewer therapy applications could give it an advantage⁤ over existing catheter ablation systems.

what ‍is the Aveir wireless pacemaker, and what’s⁤ innovative about it?

The Aveir wireless pacemaker is a ⁤leadless (without⁢ wires) pacing system. The innovation lies in its conduction system pacing (CSP) technology. CSP ⁢mimics the heart’s natural⁣ electrical rhythm by stimulating the left ⁤leg block area.

What milestones has the Aveir wireless pacemaker achieved?

Several milestones have been reached with‍ the Aveir wireless pacemaker, including:

Successful implantation

Achievement of left⁢ ventricular stimulation.

What is “breakthrough device” status, and what ⁢does it mean for Aveir?

The Food and⁤ Drug Management (FDA) has granted “breakthrough device” status to both the Aveir CSP system and its ⁤associated ICD electrode. This designation underscores the potential impact of these technologies, suggesting they could offer significant improvements over existing treatments.

What is the ASCEND ‍CSP study?

The ASCEND CSP study is a larger approval study currently underway. ‍it plans to enroll up to 414 patients at 70 locations globally.The goal of‍ this study is ⁢to finalize the assessment of ⁤the⁣ Aveir system’s safety and effectiveness.

What are the expected ⁣impacts⁢ of these advancements?

These advancements in cardiology‍ signal Abbott’s commitment to innovation. ⁤The successful growth and market introduction of these systems are ⁤expected to ⁣be crucial for the company’s future market position.

Can you summarize the key details of the technologies?

Certainly! Here’s a table‍ to summarize the key features of the technologies discussed:

| Feature ‍ ⁤ | Volt PFA System⁣ ⁢ ⁤ |⁢ Aveir Wireless ‍Pacemaker (CSP) |

| ———————- | —————————————— | ———————————————– |

| Primary Focus |⁢ Atrial Fibrillation Treatment ‍ ⁢ | Wireless ‍Pacing & Cardiac rhythm Management |

| Technology ‍ ⁢| Pulsed ⁤field Ablation (PFA)⁣ ‍ | Conduction System Pacing (CSP) ⁣ |

| Study ‍Outcomes ⁤ | Safe and effective, long-term outcomes | Demonstrated safety and ⁢performance⁢ |

| Key Benefit ⁢ ‍ ⁢ |‍ Potentially fewer therapy applications ⁤ | Mimics natural heart rhythm stimulation ‍⁤ |

| FDA Status